The US FDA has granted Fast-Track Designation to the groundbreaking antimicrobial peptide OMN6 from Israel’s Omnix Medical (see here previously). OMN6 is commencing a Phase II trial in patients with two deadly hospital-acquired pneumonias – HABP and VABP.

https://omnixmedical.com/2024/02/20/omnix-medical-granted-fast-track-designation-by-u-s-fda-for-its-next-generation-anti-infective-omn6/